Stock Track | Halozyme Therapeutics Soars 6.43% Premarket on Raised 2025 Outlook and Share Buyback

Stock Track01-08

Halozyme Therapeutics (HALO) stock surged 6.43% in the premarket session on Wednesday, outperforming the broader markets. The biopharmaceutical company's shares soared after it raised its financial guidance for 2025, reflecting robust growth prospects across key metrics.

In a press release, Halozyme reiterated its 2024 financial guidance, indicating that its business performance last year met expectations. However, the company significantly raised its 2025 outlook, projecting strong growth driven by increased royalty revenue and product sales.

For the full year 2025, Halozyme now expects total revenue to range between $1.15 billion and $1.23 billion, representing a year-over-year growth of 16% to 23%. The company attributed the anticipated revenue growth to the strong performance of its existing products, including VYVGART, Darzalex SC, and Phesgo, as well as the recent launches of Ocrevus Zunovo, Tecentriq Hybreza, and Opdivo Qvantig.

Furthermore, Halozyme raised its 2025 guidance for adjusted EBITDA to $755 million to $805 million, reflecting a 24% to 32% increase compared to 2024. The company also forecast its non-GAAP diluted earnings per share to grow 21% to 30%, ranging from $4.95 to $5.35 in 2025.

In addition to the improved financial guidance, Halozyme announced a new $250 million accelerated share repurchase program, signaling its confidence in future growth prospects and commitment to enhancing shareholder value.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1149995926?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-08 22:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1149995926","market":"us","top_or_hot":-1,"title":"Stock Track | Halozyme Therapeutics Soars 6.43% Premarket on Raised 2025 Outlook and Share Buyback","media":"Stock Track","content":"<p>Halozyme Therapeutics (HALO) stock surged 6.43% in the premarket session on Wednesday, outperforming the broader markets. The biopharmaceutical company's shares soared after it raised its financial guidance for 2025, reflecting robust growth prospects across key metrics.</p>\n\n<p>In a press release, Halozyme reiterated its 2024 financial guidance, indicating that its business performance last year met expectations. However, the company significantly raised its 2025 outlook, projecting strong growth driven by increased royalty revenue and product sales.</p>\n\n<p>For the full year 2025, Halozyme now expects total revenue to range between $1.15 billion and $1.23 billion, representing a year-over-year growth of 16% to 23%. The company attributed the anticipated revenue growth to the strong performance of its existing products, including VYVGART, Darzalex SC, and Phesgo, as well as the recent launches of Ocrevus Zunovo, Tecentriq Hybreza, and Opdivo Qvantig.</p>\n\n<p>Furthermore, Halozyme raised its 2025 guidance for adjusted EBITDA to $755 million to $805 million, reflecting a 24% to 32% increase compared to 2024. The company also forecast its non-GAAP diluted earnings per share to grow 21% to 30%, ranging from $4.95 to $5.35 in 2025.</p>\n\n<p>In addition to the improved financial guidance, Halozyme announced a new $250 million accelerated share repurchase program, signaling its confidence in future growth prospects and commitment to enhancing shareholder value.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Halozyme Therapeutics Soars 6.43% Premarket on Raised 2025 Outlook and Share Buyback</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Halozyme Therapeutics Soars 6.43% Premarket on Raised 2025 Outlook and Share Buyback\n</h2>\n\n<h4 class=\"meta\">\n\n2025-01-08 22:35 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Halozyme Therapeutics (HALO) stock surged 6.43% in the premarket session on Wednesday, outperforming the broader markets. The biopharmaceutical company's shares soared after it raised its financial ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HALO","symbol_name":"奥洛兹美医疗","start_time":0,"source_url":"","article_id":"1149995926","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1149995926","pubTimestamp":1736346939,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Halozyme Therapeutics  stock surged 6.43% in the premarket session on Wednesday, outperforming the broader markets. The biopharmaceutical company's shares soared after it raised its financial guidance for 2025, reflecting robust growth prospects across key metrics.In a press release, Halozyme reiterated its 2024 financial guidance, indicating that its business performance last year met expectations. However, the company significantly raised its 2025 outlook, projecting strong growth driven by in","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HALO":"奥洛兹美医疗"},"translate_title":"Halozyme Therapeutics因2025年展望上调和股票回购而盘前飙升6.43%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HALO":1},"content_text":"Halozyme Therapeutics (HALO) stock surged 6.43% in the premarket session on Wednesday, outperforming the broader markets. The biopharmaceutical company's shares soared after it raised its financial guidance for 2025, reflecting robust growth prospects across key metrics.\nIn a press release, Halozyme reiterated its 2024 financial guidance, indicating that its business performance last year met expectations. However, the company significantly raised its 2025 outlook, projecting strong growth driven by increased royalty revenue and product sales.\nFor the full year 2025, Halozyme now expects total revenue to range between $1.15 billion and $1.23 billion, representing a year-over-year growth of 16% to 23%. The company attributed the anticipated revenue growth to the strong performance of its existing products, including VYVGART, Darzalex SC, and Phesgo, as well as the recent launches of Ocrevus Zunovo, Tecentriq Hybreza, and Opdivo Qvantig.\nFurthermore, Halozyme raised its 2025 guidance for adjusted EBITDA to $755 million to $805 million, reflecting a 24% to 32% increase compared to 2024. The company also forecast its non-GAAP diluted earnings per share to grow 21% to 30%, ranging from $4.95 to $5.35 in 2025.\nIn addition to the improved financial guidance, Halozyme announced a new $250 million accelerated share repurchase program, signaling its confidence in future growth prospects and commitment to enhancing shareholder value.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"buyback,movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1149995926"}